No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for IN8bio, Inc. (INAB) stock was $1.45 as of Oct 6, 2026, 10:00 AM EDT, up 2.11% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -40.4% · 3-year avg -63.6%/yr · 5-year avg -62.9%/yr
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer.
Biotechnology · New York City, NY
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.34
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.25
vs Estimate
$-0.37
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1INAB | $13.91M | $1.45 | +2.11% | -40.44% | -62.88% | N/A | N/A |
| 2HIND | $13.69M | $1.95 | +1.04% | -74.83% | -92.93% | N/A | vs INAB |
| 3CTXR | $14.28M | $0.52 | +0.06% | -61.87% | -60.04% | -46.34% | vs INAB |
| 4CLRB | $13.39M | $1.68 | +0.32% | -49.83% | -60.51% | -55.35% | vs INAB |
| 5KPTI | $15.00M | $0.66 | -1.31% | -89.38% | -62.18% | -41.85% | vs INAB |
| 6DARE | $12.68M | $0.85 | +0.40% | -61.15% | -46.35% | -39.10% | vs INAB |
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 3 analysts
Average Price Target
$7.00
+382.8% upside
Low
$5.00
Current
$1.45
High
$10.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.34 | $-0.34 | $-0.34 | 2 |
| Quarter ending Dec 2026 | $-0.35 | $-0.35 | $-0.35 | 2 |
| Quarter ending Mar 2027 | $-0.33 | $-0.33 | $-0.33 | 1 |
| Quarter ending Jun 2027 | $-0.34 | $-0.34 | $-0.34 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.11 | $-1.11 | $-1.11 | 2 |
| FY 2027 | $-0.95 | $-0.95 | $-0.95 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $47.67M | $47.67M | $47.67M | 3 |
| FY 2027 | $1.66M | $1.66M | $1.66M | 2 |
